Company profile
Cresco Labs Inc.
OTC: CRLBF · Healthcare · Drug Manufacturers - Specialty & Generic
#190 of 1,418 Healthcare companies by revenue33rd-percentile growth
EA Score
37DFH 53DQ 6GM —SS 66
v0.1 · 55/100 weight · provisional
↑ workforce scale, return on assets · ↓ disclosure history, filing timeliness
Methodology →Revenue TTM
$641.8M
Rev growth YoY (TTM)
-8.7%
Net income (FY)
-$135.4M
Employees
2,900
as of 2026-08-13
Market cap
$272.8M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$655.8M$655.8M2025
Net income-$135.4M-$135.4M2025
Operating income-$28.0M-$28.0M2025
Total assets$1.2B$1.2B2025
Liabilities$944.8M$944.8M2025
Equity$340.4M$340.4M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Dispensary66%
Wholesale34%
By geography
Not disclosed.
The read
What is Cresco Labs Inc.’s revenue?
Cresco Labs Inc. booked $655.8M in FY2025 revenue, contracting 9.5% year over year — slower than 67% of Healthcare companies we track, at a -20.6% net margin.
Peers · Healthcare
Sienna Senior Living Inc.75B+Avanos Medical, Inc.73BUltragenyx Pharmaceutical Inc.58CDoximity, Inc.73B10x Genomics, Inc.67BAxsome Therapeutics, Inc.59CNeighbors
Cook →Key facts
CEOCharles Bachtell
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersChicago, IL
ExchangeOTC: CRLBF
Employees2,900
IPO date2018-12-03
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.